Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/sji.13131

http://scihub22266oqcxt.onion/10.1111/sji.13131
suck pdf from google scholar
34936112!ä!34936112
PDF vom PMID34936112  :  Publisher
PDF vom PMID34936112

suck abstract from ncbi

pmid34936112
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges #MMPMID34936112
  • Pourgholaminejad A; Pahlavanneshan S; Basiri M
  • Scand J Immunol 2022[Feb]; 95 (2): e13131 PMID34936112show ga
  • The role of the immune system against coronavirus disease 2019 (COVID-19) is unknown in many aspects, and the protective or pathologic mechanisms of the immune response are poorly understood. Pro-inflammatory cytokine release and a consequent cytokine storm can lead to acute respiratory distress syndrome (ARDS) and result in multi-organ failure. There are many T cell subsets during anti-viral immunity. The Th17-associated response, as a pro-inflammatory pathway, and its consequent outcomes in many autoimmune disorders play a fundamental role in progression of systemic hyper-inflammation during COVID-19. Therapeutic strategies based on immunomodulation therapy could be helpful for targeting hyper-inflammatory immune responses in COVID-19, especially Th17-related inflammation and hyper-cytokinemia. Cell-based immunotherapeutic approaches including mesenchymal stem cells (MSCs), tolerogenic dendritic cells (tolDCs) and regulatory T cells (Tregs) seem to be promising strategies as orchestrators of the immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we highlight Th17-related immunopathology of SARS-CoV-2 infection and discuss cell-based immunomodulatory strategies and their mechanisms for regulation of the hyper-inflammation during COVID-19.
  • |Adoptive Transfer/methods[MESH]
  • |COVID-19/immunology/*pathology/*therapy[MESH]
  • |Cell- and Tissue-Based Therapy/methods[MESH]
  • |Cytokine Release Syndrome/*pathology[MESH]
  • |Cytokines/blood[MESH]
  • |Dendritic Cells/transplantation[MESH]
  • |Humans[MESH]
  • |Immunomodulation/*immunology[MESH]
  • |Mesenchymal Stem Cell Transplantation[MESH]
  • |SARS-CoV-2/immunology[MESH]
  • |T-Lymphocytes, Regulatory/transplantation[MESH]
  • |Th17 Cells/*immunology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    e13131 2.95 2022